{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:16:34Z","timestamp":1761178594897,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.canrad.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T07:34:32Z","timestamp":1683272072000},"page":"296-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma: Long-term results of RTF3 regimen"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-0773","authenticated-orcid":false,"given":"B.","family":"Allignet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8230-394X","authenticated-orcid":false,"given":"P.","family":"Merle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6757-3477","authenticated-orcid":false,"given":"J.Y.","family":"Mabrut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-0902","authenticated-orcid":false,"given":"K.","family":"Mohkam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-1269","authenticated-orcid":false,"given":"F.","family":"Mornex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.01.004_bib0180","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"year":"2021","series-title":"SEER Cancer Statistics Review, 1975-2018. posted to the SEER web site","author":"Howlader","key":"10.1016\/j.canrad.2023.01.004_bib0185"},{"key":"10.1016\/j.canrad.2023.01.004_bib0190","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.canrad.2023.01.004_bib0195","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Galle P.R., Forner A., Llovet J.M., Mazzaferro V., Piscaglia F., Raoul J.-L., et al. EASL Clinical Practice Guidelines: Management of hepatocellular, carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0200","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0168-8278(03)00349-0","article-title":"Screening for hepatocellular carcinoma in cirrhosis","volume":"39","author":"Bolondi","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0205","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MCG.0000000000000859","article-title":"Medicaid and uninsured hepatocellular carcinoma patients have more advanced tumor stage and are less likely to receive treatment","volume":"52","author":"Wang","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0210","doi-asserted-by":"crossref","first-page":"e115834","DOI":"10.1371\/journal.pone.0115834","article-title":"Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis","volume":"9","author":"Zhu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canrad.2023.01.004_bib0215","doi-asserted-by":"crossref","first-page":"100508","DOI":"10.18632\/oncotarget.20119","article-title":"What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? A systematic review and network meta-analysis","volume":"8","author":"Xie","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canrad.2023.01.004_bib0220","first-page":"97","article-title":"Transcatheter arterial chemoembolization (TACE) combined with \u03b3-knife compared to TACE or \u03b3-knife alone for hepatocellular carcinoma","author":"Cai","year":"2018","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.canrad.2023.01.004_bib0225","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","article-title":"Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma a systematic review and meta-analysis","volume":"1","author":"Huo","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0230","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs. sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0235","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","article-title":"Median follow-up in clinical trials","volume":"9","author":"Shuster","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0240","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3748\/wjg.v21.i4.1207","article-title":"Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy","volume":"21","author":"Yamamoto","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0250","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2011.11.058","article-title":"Stereotactic body radiation therapy in recurrent hepatocellular carcinoma","volume":"84","author":"Huang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.004_bib0255","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13014-018-1048-4","article-title":"Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease","volume":"13","author":"Gerum","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0260","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1259\/bjr\/33521596","article-title":"Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma","volume":"80","author":"Zhou","year":"2007","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0265","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1007\/s13277-015-3144-5","article-title":"The comparison of outcomes between hypofractionated and conventional 3D-CRT regimens used in combination with TACE as first-line treatment of advanced hepatocellular carcinoma","volume":"36","author":"Wang","year":"2015","journal-title":"Tumor Biol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0270","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00432-014-1697-0","article-title":"Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma","volume":"140","author":"Yoon","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0275","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2014.05.002","article-title":"Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma","volume":"111","author":"Culleton","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0280","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","article-title":"Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma","volume":"100","author":"Sapir","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.004_bib0285","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1186\/s12885-018-4696-8","article-title":"Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis","volume":"18","author":"Bettinger","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2023.01.004_bib0290","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000505739","article-title":"Stereotactic body radiotherapy combined with transcatheter arterial chemoembolization versus stereotactic body radiotherapy alone as the first-line treatment for unresectable hepatocellular carcinoma: a meta-analysis and systematic review","volume":"64","author":"Zhao","year":"2019","journal-title":"Chemotherapy"},{"key":"10.1016\/j.canrad.2023.01.004_bib0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijrobp.2022.05.021","article-title":"Combination transarterial chemoembolization and stereotactic body radiation therapy for unresectable single large hepatocellular carcinoma: results from a prospective phase 2 trial","volume":"114","author":"Buckstein","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.004_bib0300","doi-asserted-by":"crossref","first-page":"e0174929","DOI":"10.1371\/journal.pone.0174929","article-title":"Target localization of 3D versus 4D cone beam computed tomography in lipiodol-guided stereotactic radiotherapy of hepatocellular carcinomas","volume":"12","author":"Chan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canrad.2023.01.004_bib0305","doi-asserted-by":"crossref","first-page":"616027","DOI":"10.3389\/fonc.2021.616027","article-title":"MR-guided radiotherapy for liver malignancies","volume":"11","author":"Boldrini","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0310","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0315","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.canrad.2023.01.004_bib0320","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cam4.5125","article-title":"TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis","volume":"12","author":"Brown","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.canrad.2023.01.004_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-81176-w","article-title":"Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study","volume":"11","author":"Chu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.canrad.2023.01.004_bib0330","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.01.004_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/815105","article-title":"Liver injury induced by anticancer chemotherapy and radiation therapy","volume":"2013","author":"Maor","year":"2013","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0340","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00432-015-1974-6","article-title":"Radiation-induced fibrosis: mechanisms and implications for therapy","volume":"141","author":"Straub","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0345","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2217\/fon-2016-0083","article-title":"Conformal radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma: is it safe?","volume":"12","author":"Mohkam","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.canrad.2023.01.004_bib0350","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.2217\/fon-2019-0127","article-title":"Neoadjuvant conformal radiotherapy before liver transplantation for hepatocellular carcinoma: a propensity score matched analysis of postoperative morbidity and oncological results","volume":"15","author":"Mourad","year":"2019","journal-title":"Future Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:37:09Z","timestamp":1761136629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321823000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1278321823000641"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.01.004","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma: Long-term results of RTF3 regimen","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}